Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/159917
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGonzález-Domíngues, Raúl-
dc.contributor.authorSayago, Ana-
dc.contributor.authorFernández-Recamales, Ángeles-
dc.date.accessioned2020-05-13T07:15:23Z-
dc.date.available2020-05-13T07:15:23Z-
dc.date.issued2017-12-15-
dc.identifier.issn1570-0232-
dc.identifier.urihttp://hdl.handle.net/2445/159917-
dc.description.abstractAlzheimer's disease is a complex neurodegenerative disorder characterized by a multi-factorial etiology, not completely understood to date. In this context, the application of metabolomics is emerging in the last years because of its potential to monitor molecular alterations associated with disease pathogenesis and progression, as well as to discover candidate diagnostic biomarkers. However, the huge heterogeneity and dynamism of the human metabolome makes impossible the simultaneous determination of the entire set of metabolites from complex biological samples. Thus, the most common strategy to get a comprehensive overview of the organism's phenotypic expression is the combined use of complementary metabolomic platforms. In this review, we summarize the advantages and limitations of the most important analytical techniques usually employed in metabolomics, including nuclear magnetic resonance, direct infusion mass spectrometry and hyphenated approaches based on the coupling of orthogonal separation mechanisms (i.e. liquid chromatography, gas chromatography, capillary electrophoresis) with mass spectrometry. Moreover, the suitability of metabolomics to unravel the complex pathology underlying to Alzheimer's disease is also presented. (C) 2017 Elsevier B.V. All rights reserved.-
dc.format.extent18 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier B.V.-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.jchromb.2017.02.008-
dc.relation.ispartofJournal Of Chromatography B-Analytical Technologies In The Biomedical And Life Sciences, 2017, vol. 1071, p. 75-92-
dc.relation.urihttps://doi.org/10.1016/j.jchromb.2017.02.008-
dc.rightscc-by-nc-nd (c) Elsevier B.V., 2017-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es-
dc.subject.classificationMalaltia d'Alzheimer-
dc.subject.classificationMetabolòmica-
dc.subject.classificationEspectrometria de masses-
dc.subject.classificationRessonància magnètica nuclear-
dc.subject.otherAlzheimer's disease-
dc.subject.otherMetabolomics-
dc.subject.otherMass spectrometry-
dc.subject.otherNuclear magnetic resonance-
dc.titleMetabolomics in Alzheimer's disease: The need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec678074-
dc.date.updated2020-05-13T07:15:23Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Nutrició, Ciències de l'Alimentació i Gastronomia)

Files in This Item:
File Description SizeFormat 
678074.pdf1.47 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons